Erbitux gets Swiss OK
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA receives the first approval for colorectal cancer therapy Erbitux (cetuximab), with clearance in Switzerland Dec. 1 for use in combination with irinotecan. The application was submitted to Swissmedic and the EMEA at the end of June; EU marketing authorization is expected in mid-2004. Erbitux is pending at FDA with a mid-February user fee goal. Bristol/ImClone resubmitted the Erbitux NDA August 14 based on new data from a Merck KGaA study (1Pharmaceutical Approvals Monthly June 1, 2003, In Brief)...
You may also be interested in...
New Erbitux data = new chance
Bristol-Myers Squibb and ImClone "plan to discuss" the positive results of a Merck KGaA-sponsored study of Erbitux with FDA "as they relate to the U.S. filing for cetuximab in advanced colorectal cancer." FDA refused to file the BLA for the epidermal growth factor receptor antagonist in December 2001, and Bristol has projected a new BLA submission in 2004. Merck KGaA's Phase II study, presented at the American Society of Oncology annual meeting in Chicago June 1, compared cetuximab monotherapy and combination use with irinotecan in patients with irinotecan-refractory, EGFR-expressing colorectal cancer. Response rate was 22.9% for the combo vs. 10.8% for cetuximab-alone, median time to progression was 4.1 months vs. 1.5 months, overall rate of disease control was 55.5% vs. 32.4%, and median survival was 8.6 months vs. 6.9 months. The differences in response rate and time to progression were statistically significant, the companies report. Merck KGaA plans a mid-2003 European filing and a 2004 launch...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.